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Abstract
Background: Obesity modulates inflammation and activation of immune pathways which can lead to liver complications.
We aimed at identifying expression patterns of inflammatory and immune response genes specifically associated with
obesity and NASH in the liver of morbidly obese patients.
Methodology/Principal Findings: Expression of 222 genes was evaluated by quantitative RT-PCR in the liver of morbidly
obese patients with histologically normal liver (n=6), or with severe steatosis without (n=6) or with NASH (n=6), and in
lean controls (n=5). Hepatic expression of 58 out of 222 inflammatory and immune response genes was upregulated in
NASH patients. The most notable changes occurred in genes encoding chemokines and chemokine receptors involved in
leukocyte recruitment, CD and cytokines involved in the T cell activation towards a Th1 phenotype, and immune
semaphorins. This regulation seems to be specific for the liver since visceral adipose tissue expression and serum levels of
MCP1, IP10, TNFa and IL6 were not modified. Importantly, 47 other genes were already upregulated in histologically normal
liver (e.g. CRP, Toll-like receptor (TLR) pathway). Interestingly, serum palmitate, known to activate the TLR pathway, was
increased with steatosis.
Conclusion/Significance: The liver of obese patients without histological abnormalities already displayed a low-grade
inflammation and could be more responsive to activators of the TLR pathway. NASH was then characterized by a specific
gene signature. These findings help to identify new potential actors of the pathogenesis of NAFLD.
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Introduction
The incidence of overweight and obesity is rapidly increasing in
many Western countries and is associated with the development of
type 2 diabetes, hypertension and Non Alcoholic Fatty Liver
Disease (NAFLD). NAFLD is one of the most common forms of
chronic liver diseases [1]. Liver biopsies of patients with NAFLD
show a spectrum of pathological changes ranging from simple
steatosis to steatohepatitis (Non Alcoholic Steato-Hepatitis,
NASH) and steatofibrosis leading, in some cases, to cirrhosis and
hepatocellular carcinoma. Indeed, 20% of patients with biopsies-
proven NASH may progress to cirrhosis [1].
NAFLD are frequently associated with visceral obesity, insulin
resistance and metabolic syndrome [2] but predisposing and
environmental factors could also be involved. Obesity modulates
inflammation and activation of immune pathways which can affect
hepatic lipid metabolism leading to hepatic injury, NASH and
fibrosis. Adipose tissue and gut are potential players in the
alteration of hepatic metabolism and inflammation [3]. Adipose
tissue of obese patients is inflamed and the recruitment and
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as Monocyte Chemoattractant Protein 1 (MCP1) and osteopontin
are the principal effectors of this inflammation [4–6]. Inflamma-
tion causes adipocyte insulin resistance resulting in increased
lipolysis and serum free fatty acids (FFA) flux, alteration of
adipokine secretion and consequently hepatic fat accumulation
and insulin resistance [7–9].
In NAFLD, adipose tissue substantially contributes to systemic
TNFa, MCP1, IL6, and adiponectin which modify the hepatic
inflammatory/immune system. We have shown that IL6-stimu-
lated CRP and hepcidin expression in adipose tissue is associated
with the elevated circulating levels of CRP and hypoferremia in
morbidly obese patients independently of NASH [10–12]. Patients
with NAFLD also seem to have an increased intestinal
permeability associated with loss of integrity of epithelial tight
junctions which could lead to increased levels of circulating
lipopolysaccharide (LPS) [13]. Activation of cells including
Kupffer cells by LPS triggers the production of reactive oxygen
species and pro-inflammatory cytokines in the liver, resulting in
NAFLD [14].
Alteration in Natural Killer T (NKT) cells number and/or
activity and activation of the adaptive immune system could also
promote the liver alterations. NKT cells can produce both T
helper 1 (Th1) and T helper 2 (Th2) associated cytokines steering
the immune system into either inflammation or tolerance. An
inverse correlation has been reported between the severity of
steatosis and NKT cell number in mice and the reduction in the
NKT cell number was associated with an increased hepatic
production of Th1 cytokines [3]. In NAFLD patients, peripheral
NKT cell number is decreased [15]. Activation of Kupffer cells,
oxidative stress, reduction in regulatory T cells, and the altered
profiles of adipokines (leptin, resistin versus adiponectin) could also
lead to the disruption of the physiological tolerance of the liver to
portal antigens [3]. Indeed, IgG antibodies against lipid peroxi-
dation-derived antigens have been observed in patients with
NAFLD and are associated with advanced fibrosis [16].
The inflammation and immune reactions in the progression of
normal liver to steatosis, and then NASH are not well
characterized. In this paper, we have focused on the differential
expression of genes related to inflammation and immune response
specifically associated with obesity, steatosis and NASH in liver of
morbidly obese patients. To this aim, a quantitative approach was
used focussing at most inflammatory pathways reported in the
hepatic complications induced by obesity and chronic alcohol
consumption in mice and humans.
Results
Clinical and biochemical data
Characteristics of the morbidly obese patients are given in
Table 1, according to the severity of steatosis (S0: without steatosis,
n=6; S3: with severe steatosis, n=6) and the presence of NASH
(NASH, n=6) determined on liver biopsies. All NASH patients
have severe steatosis and a NAFLD activity score (NAS) $5. All
the obese patients have the same hepatic fibrosis stage (F1). A
significant difference was observed in the genders of NASH obese
patients and the S0 and S3 obese patients.
Genes upregulated with NASH
The goal of this study was to better characterize the
inflammation and immune reaction in NAFLD patients. To this
aim, we examined the expression levels of 222 selected genes
related to inflammation and immune response including the CD,
chemokines, semaphorins/plexins, interleukin, IFN, TNFa,
TGFb,N F kB and Toll-like receptor pathways (Table S1) by a
quantitative RT-PCR approach. Among the 222 inflammatory
and immune response genes tested, 192 were detected in liver in
our experimental conditions (Table S1).
A number of comparisons were then performed to detect genes
potentially involved in obesity, liver steatosis and NASH. The first
analysis compared expression profiles between NASH and S3
patients. We defined as a NASH specific gene, a gene which was
upregulated more than 1.4 fold in NASH patients compared to S3
patients and, evidently, to S0 patients and controls (lean patients
without liver disease). 58 genes were upregulated in NASH
patients and can be separated into two groups: 38 genes were
specifically upregulated in NASH patients (and not in S0 and S3
patients) and 20 genes were upregulated in S0 and S3 patients and
further increased in NASH patients (Table 2). Interestingly, as
illustrated in Figure 1, 15 genes upregulated in NASH patients
encoded chemokines and chemokine receptors involved in
leukocyte recruitment including the couples CXCL8/CXCR1;
CXCL1, 3/CXCR2; CCL3-5/CCR5 and the chemokines
CXCL9-11 and CCL2 (MCP1). In addition, CD62E (E-Selectin)
and CD44 which could be involved in leukocyte recruitment into
inflammation sites were strongly upregulated in NASH patients
(Figure 1). Some of the NASH specific genes encoded cytokines
and molecules involved in the interaction and co-stimulation
between antigen-presenting cells (APC) and T lymphocytes
Table 1. Characteristics of the morbidly obese patients.
S0 S3 NASH
Sex (female/male) 5/1 5/1 1/5
Age (years) 36.265.9 36.063.4 43.264.0
BMI (kg/m
2) 43.860.6 44.361.9 40.261.3*
ALT (IU/L) 17.563.9 35.164.2* 58.069.7*
/1
AST (IU/L) 20.063.8 24.962.2* 35.264.4*
/1
GGT (IU/L) 19.562.6 33.767.3* 57.2615.2*
Alkaline phosphatase (IU/L) 74.768.9 87.3610.6 75.063.4
Albumin (g/L) 37.961.0 42.161.5* 43.961.3*
Total bilirubin (mmol/L) 8.862.4 7.160.5 10.461.7
1
Conjugated bilirubin (mmol/L) 1.860.7 2.160.1 2.660.2
Fasting insulin (mIU/L) 7.160.9 13.763.5 26.066.3*
Fasting glucose (mmol/L) 4.960.1 5.460.3 7.361.3*
HOMA-IR 1.660.2 3.561.1* 7.961.7*
/1
Triglycerides (mmol/L) 0.9960.14 1.6160.27 4.4461.44*
/1
Free fatty acids (mmol/L) 0.4460.06 0.6460.05 0.4760.08
Total cholesterol (mmol/L) 4.7460.42 5.8960.45 6.3460.42*
HDL cholesterol (mmol/L) 1.4060.11 1.5060.14 1.1460.07
LDL cholesterol (mmol/L) 2.9060.44 3.6660.34 3.1860.27
NAFLD Activity Score (n) 0 (6) 3 (6) 5 (5) 6 (1)
Grade of steatosis (n) 0 (6) 3 (6) 3 (6)
Lobular inflammation (n) 0 (6) 0 (6) 1 (5) 2 (1)
Hepatocellular ballooning (n) 0 (6) 0 (6) 1 (6)
Fibrosis (n) 1 (6) 1 (6) 1 (6)
S0: patients with normal liver histology, S3: patients with severe steatosis,
NASH: patients with severe steatosis and NASH. Data are expressed as
mean6SEM and were compared by using the non parametric Kruskal-Wallis
test.
*P,0.05 compared with S0 patients and.
1P,0.05 compared with S3 patients.
doi:10.1371/journal.pone.0013577.t001
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Gene symbol Controls S0 S3 NASH Fold NASH vs S3 P NASH vs S3
CD
CD62E/E-Selectin 1.0060.35 4.3961.37* 9.1962.52* 50.28615.99* 5.5 0.005
CD69/EA1 1.0060.16 1.6360.25 1.7660.47 6.2261.78* 3.5 0.016
CD54/ICAM1 1.0060.16 1.7660.24* 1.8860.21* 6.4861.10* 3.5 0.006
CD80/B7-1 1.0060.06 2.7960.70* 2.5960.49* 8.6262.22* 3.3 0.025
CD11b/ITGAM 1.0060.18 1.2060.13 1.3860.20 4.15 61.30* 3.0 0.006
CD44 1.0060.18 1.7760.19* 2.0360.16* 4.6360.89* 2.3 0.006
CD18/LFA1 1.0060.21 0.9760.14 1.3160.14 2.8560.59* 2.2 0.010
CD86/B7-2 1.0060.25 1.7960.23 2.2060.26 4.8360.79* 2.2 0.008
CD28 1.0060.15 1.3360.12 1.6960.21 3.5760.67* 2.1 0.046
CD48/LFA3 1.0060.27 1.1360.17 1.4560.12 2.9060.59* 2.0 0.010
CD68 1.0060.10 2.2060.19* 2.2560.20* 4.1260.42* 1.8 0.010
Chemokines and chemokine receptors
CXCL8/IL8 1.0060.10 7.2162.79* 8.1261.76* 73.71627.14* 9.1 0.006
CCL4/MIP1b 1.0060.15 1.1760.18 1.8160.34 7.7861.95* 4.3 0.006
CXCL11 1.0060.23 1.2560.16 1.7260.19 7.1963.08* 4.2 0.010
CCL2/MCP1 1.0060.32 2.5860.48* 3.0860.32* 12.5265.78* 4.1 0.037
CXCL1/GROa 1.0060.49 2.4661.42 7.1363.72 26.0367.49* 3.7 0.016
CCL3/MIP1a 1.0060.19 2.4560.35* 3.8061.39* 14.1961.64* 3.7 0.011
CXCL10/IP10 1.0060.32 0.8160.20 1.1160.27 3.5860.66* 3.2 0.010
CXCR2/IL8RB 1.0060.21 1.6660.42 1.9360.30 6.1260.97* 3.2 0.006
CCR7 1.0060.15 1.4860.09* 2.2860.40* 6.6362.06* 2.9 0.045
CXCL3/GROc 1.0060.36 2.9160.76* 5.0261.21* 13.8263.59* 2.8 0.028
CXCL9 1.0060.29 0.7460.12 1.1060.12 2.9160.52* 2.7 0.016
CCL5/RANTES 1.0060.21 0.8860.12 0.9260.10 2.4860.89* 2.7 0.037
CXCR1/IL8RA 1.0060.18 2.5460.86* 2.7760.52* 7.3961.31* 2.7 0.010
CCR5 1.0060.14 0.8460.11 0.9460.03 1.8760.24* 2.0 0.004
CXCL16 1.0060.11 1.1960.18 1.5560.17 2.3860.39* 1.5 0.025
Semaphorins and plexins
PLXNC1 1.006 0.07 1.3560.23 1.4060.12 5.7062.28* 4.1 0.010
SEMA4A 1.006 0.20 1.556 0.42 1.4860.24 5.3661.66* 3.6 0.016
SEMA7A 1.0060.25 0.8760.09 0.9760.08 2.8760.71* 3.0 0.010
SEMA4D 1.0060.19 1.2560.13 1.4260.10 3.4361.22* 2.4 0.037
Interleukin pathway
IL6 1.0060.42 4.0160.96 3.5861.67 21.2766.78* 5.9 0.011
IL1B 1.006 0.37 0.9060.17 1.4160.27 7.6862.04* 5.4 0.003
IL7R 1.0060.23 1.3960.15 1.2960.12 4.4061.56* 3.4 0.028
IL1RN 1.0060.10 1.6160.25* 1.7860.32* 5.1560.77* 2.9 0.010
IL3RA 1.0060.23 1.0660.25 1.2660.11 3.3261.12* 2.6 0.016
NFL3 1.0060.11 1.626 0.20* 1.8660.24* 4.9060.80* 2.6 0.004
IL2RG 1.0060.16 0.9160.09 1.0160.12 2.5660.53* 2.5 0.016
IL18 1.0060.33 1.0860.14 1.1660.12 2.4460.54* 2.1 0.010
IL13RA2 1.0060.18 1.0260.14 0.8960.18 1.8660.32* 2.1 0.013
IL27RA 1.0060.17 0.7060.09 1.0060.15 1.9360.34* 1.9 0.028
IL1R2 1.0060.14 1.2760.24 1.2360.17 2.0260.17* 1.6 0.018
IL18BP 1.0060.06 1.4760.15 2.0060.22 3.0760.27* 1.5 0.013
JAK-STAT-SOCS pathway
SOCS3 1.0060.34 3.6360.73* 3.6460.81* 13.3763.34* 3.7 0.028
SOCS1 1.0060.11 2.0660.44* 1.7860.23* 5.1061.44* 2.9 0.025
IFN pathway
Liver Inflammation in Obesity
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IFNG 1.0060.28 0.8660.20 1.1360.21 4.1261.46* 3.6 0.039
IFI16 1.0060.25 1.4260.17 1.2060.09 3.3561.02* 2.4 0.008
TNFa and TGFb pathways
TNF 1.0060.37 0.9960.22 1.2860.30 5.9060.91* 4.6 0.004
LTB 1.0060.20 0.9060.15 1.1560.14 3.2861.05* 2.9 0.019
TNFRSF1B 1.0060.12 1.5460.10 1.4460.17 3.4060.85* 2.4 0.016
TRAF1 1.0060.12 1.0660.14 1.2460.17 2.7060.43* 2.2 0.019
TGFB1 1.0060.14 1.2760.22 1.5460.13 2.7060.51* 1.8 0.016
NFkB pathway
REL 1.0060.22 1.7260.23* 2.1860.29* 5.1261.28* 2.4 0.014
RELB 1.0060.24 2.5360.49* 2.3760.33* 5.4060.84* 2.3 0.010
NFKB2 1.0060.18 1.7760.26* 1.8660.17* 3.2260.46* 1.7 0.037
Matrix proteases and inhibitors of matrix proteases
MMP9 1.0060.26 2.3560.41* 3.6360.68* 16.5464.00* 4.6 0.011
SERPINE1/PAI1 1.0060.35 1.9560.83* 5.6560.75* 25.3964.18* 4.5 0.004
TIMP1 1.0060.12 0.9460.19 1.0460.15 2.9860.86* 2.9 0.016
PLAU 1.0060.18 1.2560.30 1.7660.27 4.7960.80* 2.7 0.006
S0: patients with normal liver histology (n=6), S3: patients with severe steatosis (n=6), NASH: patients with severe steatosis and NASH (n=6). Results are expressed
relative to control subjects (mean6SEM) and were compared by using the non parametric Kruskal-Wallis test.
*P,0.05 compared with controls.
doi:10.1371/journal.pone.0013577.t002
Table 2. Cont.
Figure 1. Upregulation of 17 genes encoding proteins involved in leukocyte recruitment in liver of NASH patients. The hepatic
expression levels of genes were analyzed by real-time quantitative PCR in morbidly obese patients with normal liver histology (S0, n=6), in morbidly
obese patients with severe steatosis (S3, n=6), and in morbidly obese patients with severe steatosis and NASH (NASH, n=6). The mRNA levels of
genes were normalized to the mRNA levels of RPLP0. Results are expressed relative to the expression levels in S0 patients and expressed as
mean6SEM. *P,0.05, compared with S0 patients.
doi:10.1371/journal.pone.0013577.g001
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Indeed, the gene expression levels of CD28, CD80 (B7-1), CD86
(B7-2) and IFNc, in addition to CD18 (LFA1), CD54 (ICAM1),
IL1b, IL6 and TNFa were upregulated only in NASH patients.
Moreover, the ratio IL10 versus IFNc was strongly decreased in
NASH patients compared to S3 patients (Figure 2A). Among the
other NASH genes, the expression of genes encoding members of
the plexin/semaphorin family (PLXNC1; SEMA 4D, 7A and 4A)
was also strongly increased in NASH patients (Table 2). We finally
confirmed the modification of the expression levels of TNFa, IL6
and CCL2 (MCP1) in NASH patients previously reported by other
groups [17–20].
Since inflamed adipose tissue could contribute to liver compli-
cations, we then evaluated in visceral adipose tissue (VAT) the gene
Figure 2. Specific upregulation of genes encoding Th1 cytokines and proteins involved in recognition between APC and T cells in
liver of NASH patients. A. The hepatic expression levels of genes were analyzed by real-time quantitative PCR in morbidly obese patients with
normal liver histology (S0, n=6), in morbidly obese patients with severe steatosis (S3, n=6), and in morbidly obese patients with severe steatosis and
NASH (NASH, n=6). The mRNA levels of genes were normalized to the mRNA levels of RPLP0. Results are expressed relative to the expression levels in
S0 patients and expressed as mean6SEM. *P,0.05, compared with S0patients;
1P=0,033. B. Scheme of recognition between APC and T cells.
doi:10.1371/journal.pone.0013577.g002
Liver Inflammation in Obesity
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was chosen for these studies since adipokines secreted by VAT are
directly delivered to the liver via the portal vein. Only 10 genes out
of the 58 NASH specific genes had a differential expression in the
VAT of NASH patients versus S3 and S0 patients (Table S2). This
indicates that the majority of the NASH markers identified are liver
specific. We then evaluated the circulating levels of two chemokines
(MCP1, IP10) and two cytokines (IL6, TNFa) which are strongly
upregulated in the liver but not in the adipose tissue of NASH
patients,ina largernumberofpatients (10lean,17 S0,24S3and 27
NASH patients). As shown in Figure 3, the expression level of these
chemokines and cytokines was similarly increased in all obese
patients compared with lean subjects with no further increase in
NASH patients. Thisresultindicates that the adipose tissue could be
the main source of these circulating factors but that their local
hepatic upregulation could play an important role in the evolution
of the liver complications.
Genes specifically upregulated with severe steatosis
We then compared expression of genes in severe steatotic livers
(S3 obese patients) with livers without any histological alterations
(S0 obese patients). Surprisingly, we identified only 3 genes which
were upregulated. They encoded SEMA3C (3.6 fold increase,
P=0.001), IL10 (3.3 fold increase, P=0.005) and CLDN10 (2.2
fold increase, P=0.002).
Genes differentially expressed in liver of S0 obese
patients compared with lean controls
Differential expression between lean controls and obese patients
without histological features of steatosis and inflammation (S0
obese patients) was evaluated to identify genes which could be
related mostly to obesity. We have previously reported in the
serum, liver and adipose tissue of morbidly obese patients that
elevated CRP expression levels were independent of metabolic
syndrome, type 2 diabetes and NASH [10]. We further show here
that CRP gene expression in liver and subcutaneous adipose tissue
was upregulated in all morbidly obese patients independently of
liver complications (Figure 4). This later study was performed only
in SCAT since control VAT was not available. Furthermore, we
identified 46 other genes upregulated in the liver of all obese
patients (Table 3) with no difference between S0, S3 and NASH
patients (data not shown). Interestingly, the expression levels of
Figure 3. Elevated serum levels of CCL2, IP10, IL6 and TNFa are dependent on obesity but not on liver complications. The serum of 9
lean patients and 70 morbidly obese patients (15 S0 patients, 23 S3 patients and 23 NASH patients with severe steatosis) were used to evaluate the
circulating levels of CCL2, IP10, IL6 and TNFa.
doi:10.1371/journal.pone.0013577.g003
Figure 4. CRP gene expression levels in function to liver complications. The expression levels of CRP were analyzed by real-time quantitative
PCR in lean subjects (n=6 for the liver; n=4 for the SCAT), in morbidly obese patients with normal liver histology (S0,n=6), in morbidly obese
patients with severe steatosis (S3, n=6), and in morbidly obese patients with severe steatosis and NASH (NASH, n=6) in liver and subcutaneous
adipose tissue. The mRNA levels of genes were normalized to the mRNA levels of RPLP0. Results are expressed relative to the expression levels in
controls and expressed as mean6SEM. *P,0.05, compared with controls.
doi:10.1371/journal.pone.0013577.g004
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LPS signaling pathways including CD14, TLR4, TLR6, TLR2,
TRAF3, TRAF6 and CHUK (IKKa) were upregulated in obese
patients compared with controls (Table 3). CD14/TLR4 and
TLR2/TLR6 are receptors for LPS and diacyl lipopeptides,
respectively [14]. Saturated fatty acids are also known to stimulate
TLR4 in macrophages [21]. We have thus evaluated the
circulating levels of LPS, total free fatty acids and palmitate in
the serum of some obese patients without or with hepatic
histological alterations. While the endotoxemia (Figure 5) and
total free fatty acids (Table 1) were not modified, the relative
expression of palmitate (Figure 5) was increased in patients with
severe steatosis or NASH compared to morbidly obese patients
without liver alterations.
Discussion
We report here that the hepatic expression levels of several
actors of the inflammatory and immune responses are modified in
all morbidly obese patients even without histological features of
steatosis or inflammation. Furthermore, the liver of obese patients
could be more responsive to activators of the TLR pathway
(endotoxin, saturated fatty acids) compared to lean subjects. The
NASH status appears preferentially associated with the cell
recruitment mediated by chemokines, a better recognition
between APC and T cells and a Th1 response steering the
immune system into inflammation.
Since a significant difference in the genders between the NASH
obese patients (predominantly male) and the S0 and S3 obese
patients (predominantly female) was present in our study, this
should be taken into account in the interpretation of the results
because a gender specific gene expression in the liver has been
reported [22,23]. However, the prevalence of NAFLD is
significantly different between genders and was higher in men
that in premenopausal women [24]. Clinical evidence in other
chronic liver diseases (i.e. chronic viral hepatitis) and evidence in
experimental models suggest that estrogen may be protective
against the NAFLD progression [24]. Nevertheless, a gender effect
can be ruled out in our studies since the same expression pattern of
hepatic genes upregulated in obesity was found in the S0, S3 and
NASH obese patients when compared with lean control subjects.
Table 3. List of the 47 genes specifically upregulated in liver
of obese patients.
Gene symbol Controls (n=5) Obese (n=18) P
Acute phase protein
CRP 1.0060.33 11.7162.20 0.003
Toll-like receptors and lipopolysaccharide pathway
TLR2 1.0060.17 4.8360.83 0.003
TLR6 1.0060.21 3.0960.32 0.002
TLR4 1.0060.13 2.8760.34 0.002
CD14 1.0060.10 1.8860.14 0.002
TRAF6 1.0060.10 1.7860.11 0.002
CHUK/IKKa 1.0060.12 1.7760.13 0.003
TRAF3 1.0060.07 1.5160.09 0.007
CD
CD180 1.0060.07 2.8960.18 0.002
CD38 1.0060.15 2.8160.26 0.007
CD36 1.0060.12 2.6960.32 0.001
CD4 1.0060.17 2.3160.19 0.003
CD62P/P-Selectin 1.0060.11 1.9060.25 0.005
CD3E 1.0060.10 1.8760.17 0.011
CD40 1.0060.14 1.7860.10 0.002
CD47 1.0060.07 1.5660.09 0.001
Chemokines and chemokine receptors
CXCR4 1.0060.13 4.0560.65 0.003
CXCL2 1.0060.29 2.4360.26 0.009
Semaphorins, plexins and neuropilins
PLXNA2 1.0060.12 2.5560.24 0.001
SEMA4F 1.0060.10 2.4160.16 0.002
SEMA5A 1.0060.11 2.4060.16 0.001
NRP2 1.0060.15 2.3560.19 0.003
SEMA5B 1.0060.11 1.9960.20 0.002
SEMA6B 1.0060.09 0.3260.04 0.001
Interleukin pathway
IL2RA 1.0060.32 7.5761.71 0.005
IL12A 1.0060.31 2.6060.35 0.013
IL16 1.0060.13 2.5260.19 0.001
IL1R1 1.0060.13 2.2060.16 0.001
IL22RA1 1.0060.09 2.1360.20 0.003
IL18R1 1.0060.19 2.0960.21 0.013
IL10RA 1.0060.14 1.9260.19 0.004
IL17R 1.0060.07 1.8860.17 0.002
IL4R 1.0060.15 1.7560.14 0.006
JAK-STAT-SOCS pathway
STAT2 1.0060.14 1.8960.16 0.006
SOCS7 1.0060.05 1.8260.11 0.003
JAK1 1.0060.11 1.7160.10 0.002
TNFa and TGFb pathways
TRAF5 1.0060.12 2.2760.23 0.003
TGFBR1 1.0060.14 1.8360.13 0.007
TNFRSF14 1.0060.08 1.4860.08 0.007
IFN pathway
Gene symbol Controls (n=5) Obese (n=18) P
IFNGR1 1.0060.09 2.8660.33 0.001
IRF6 1.0060.11 2.0460.13 0.003
IRF2 1.0060.07 2.0160.13 0.002
IFNAR1 1.0060.17 1.7960.10 0.005
IFNAR2 1.0060.04 1.7660.08 0.001
NFkB pathway
NFKBIA 1.0060.09 2.9060.36 0.001
c-Jun N-terminal kinases
MAPK8/JNK1 1.0060.08 2.3560.13 0.001
Matrix proteases
MMP14 1.0060.14 2.0960.17 0.002
Results are expressed relative to control subjects (mean6SEM) and were
compared by using the non parametric Kruskal-Wallis test.
doi:10.1371/journal.pone.0013577.t003
Table 3. Cont.
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patients. TNFa, IL6, IL1b, CXCL8 and TGFb, which are
obvious actors in the pathogenesis of progressive NAFLD, are
involved in hepatocytes death/apoptosis (TNFa, TGFb), neutro-
phil chemotaxis (CXCL8), activation of hepatic cells (TNFa,
TGFb), Mallory-Denk bodies (TNFa, TGFb) and hepatic insulin
resistance (TNFa, IL6, IL1b and SOCS3) [25]. This is in
agreement with the increased hepatic expression of IL6, TNFa
and TNF receptors which has been correlated with histological
severity in obese patients [17,18].
Several studies have suggested that the homing of circulating
lymphocytes to the liver may increase during inflammation and
enhance hepatic inflammation [26]. A recent study has demon-
strated that antibiotic treatment of ob/ob mice decreased hepatic
infiltration of CD4
+ T, CD8
+ T, NKT, B and NK cells [27]. In
our patients, we show here that gene expression of CXCL8 (IL8)
and its receptor CXCR1; CXCL1, 3 and their receptor CXCR2;
CCL3-5 and their receptor CCR5; CCL2 (MCP1); CXCL9-11;
CD62E (E-Selectin) and CD44 are strongly upregulated in NASH
patients. The chemokine expression thus appears to be more
related to inflammation and hepatocellular ballooning than to
severe steatosis. While the hepatic upregulation of these actors
could be important in the progression of liver complications, the
real contribution of these proteins for inflammatory cells
recruitment into the liver has to be determined, since systemic
levels of IL6, TNFa, IP10 and MCP1 are dependent on obesity.
The highest upregulated chemokine in liver is CXCL8 (IL8) (73
fold increases compared to the lean controls). The non
parenchymal cells but also hepatocytes should contribute to its
expression. Indeed, it has been recently reported that palmitate
induces production of IL8 in hepatocytes [28].
Although NASH is not classically considered a Th1-polarized
disease, our data suggest that an imbalance resulting from a
relative excess in pro-inflammatory Th1 cytokines such as IFNc,
and a relative deficiency of anti-inflammatory cytokines such as
IL10 is associated with NASH. Expression of genes encoding
proteins required for the interaction and co-stimulation between
APC and T cells (CD28, CD80, CD86, CD18, CD54) is also
specifically upregulated in NASH patients. It has been recently
shown that the serum CD54 (ICAM1) concentration is increased
in patients with NASH [29]. In addition, we have previously
reported the potential role of hepatic osteopontin, a Th1 cytokine,
in human NAFLD [6]. Osteopontin could enhance the activation
of the Th1 immune reaction and decrease the expression of IL10
[30–32]. In mice models of NAFLD, hepatic NKT cells and the
Th1 immune reaction have been recently implicated in the
pathogenesis of NASH. Steatohepatitis is associated with a
reduction in the number of hepatic NKT cells, a high sensitivity
to the endotoxin-induced Th1 cytokine production [33], an
impairment of the Kupffer cells functions [34], a reduction in the
serum levels of IL10 and 15 and an increase in the IL12 levels [34–
36] and excessive hepatic production of Th1 cytokines promoting
inflammation [37]. Oral immunization against liver-extracted
proteins was associated with a shift from a Th1 to Th2 immune
reaction, leading to the amelioration of NASH and glucose
intolerance in the leptin-deficient mouse model [38]. The
peripheral NKT cells number is also decreased in patients with
NAFLD [15] and an elevated Th1-cytokine profile dominated by
the production of IFNc is correlated with insulin resistance and
NASH in obese children [39]. While additional investigations are
required, all these reports and our results are in favor of a role of
Th1 reaction in the pathogenesis of NASH.
We also show, for the first time, that a large number of plexin/
semaphorin family members (28 members) are expressed in the
human liver and that the expression of the ‘‘immune semaphor-
ins’’ (SEMA4A, SEMA7A, SEMA4D, and PLXNC1) is upregu-
lated in NASH patients. SEMA4D is crucially involved in the
activation and differentiation of T cells, SEMA4A may promote
Th1 differentiation and SEMA7A stimulates macrophages to
produce pro-inflammatory cytokines [40,41].
In this study, we have validated the hepatic specificity of our
NASH markers since the same genes were not modified in VAT.
However, specific modifications of the VAT inflammation have
been correlated with the evolution of liver complications. For
example, increased infiltration of macrophages in omental adipose
tissue was associated with marked hepatic lesions in morbid
human obesity [42,43]. Prominent adipose specific deregulation of
inflammation and immune system related genes has been also
recently reported in morbidly obese patients in function to NASH,
fibrosis and type 2 diabetes [44,45]. These differences could be
due to the presence of type 2 diabetes and above all the stage of
hepatic fibrosis. All our patients have the same hepatic fibrosis
stage.
Surprisingly, we observed the presence of low-grade inflamma-
tion in the liver of morbidly obese patients without any obvious
histopathological abnormalities (S0 patients) as indicated by the
Figure 5. Elevated serum palmitate levels but not endoxin levels were present in severely steatotic obese patients. A. The serum of 9
lean patients and 70 morbidly obese patients (15 S0 patients, 23 S3 patients and 23 NASH patients with severe steatosis) was used to evaluate the
circulating levels of endotoxin. B. The abundances of palmitate as expressed relative to their values in a commercial serum sample (over 1000
individuals) were evaluated in 8 S0 patients, 9 S3 patients and 8 NASH patients.
doi:10.1371/journal.pone.0013577.g005
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response. For example, the hepatic expression of CRP, a non-
specific marker ofinflammation, waselevated inall obesepatients in
accordance with the moderate elevationofCRP plasmalevels inthe
cohort of severely obese patients [10]. The increased circulating
IL6, mainly due to adipose tissue secretion, could enhance the
hepatic expression of CRP. The upregulation of key molecules
required for the TLR signaling pathways (CD14, TLR4) were also
suggestive of a higher responsiveness to LPS or saturated fatty acids
in obese patients. A series of reports are in favor of a role of LPS,
mainly through TLR4 and CD14, in obesity induced NAFLD [46–
52]. In fasted serum from our obese patients, the endotoxin level
was similar in all groups of patients. This observation should
however be taken with caution since it could be different upon meal
challenge. In contrast, the relative amount of palmitate was
increased in steatotic patients. It is now known that the saturated
fatty acids can activate macrophages via TLR4 [21]. This hepatic
inflammation could be involved in the development of liver
complications since activation of Kupffer cells was a causal factor
for hepatic steatosis and insulin resistance [53,54].
In summary, the liver of morbidly obese patients without
histological abnormalities had a low-grade inflammation char-
acterised by the elevated expression of inflammatory markers and
could be more responsive to endotoxin and saturated fatty acids
due to the elevated expression of the Toll-like receptors. The
transient and repeated activation of the TLR pathway by the
transient upregulation of activators of the TLR could be involved
in the evolution of liver complications. Furthermore, the studies
focusing on the behavior of identified chemokines, semaphorins
and the actors leading to Th1 response on the liver functions are
attractive approaches to acquire more insight into the pathogenesis
of human NAFLD.
Materials and Methods
Study population
Patient population. 18 morbidly obese patients were recruited
through the Department of Digestive Surgery and Liver
Transplantation where they underwent bariatric surgery for their
morbid obesity (Nice hospital). Bariatric surgery was indicated for
these patients in accordance with the French Guidelines. Exclusion
criteria were: presence of hepatitis B or hepatitis C virus infection,
excessive alcohol consumption (.20 g/d) or another cause of chronic
liver diseases as previously described [6,10,11]. The characteristics of
the study groups are described in Table 1. Before surgery, fasting
blood samples were obtained and used to measure alanine amino
transferase (ALT),aspartate aminotransferase (AST),gamma glutamyl
transferase (GGT), alkaline phosphatase, albumin, total and
conjugated bilirubin. Insulin resistance was calculated by using the
homeostatic model assessment (HOMA-IR) index [55]. Surgical liver
biopsies were obtained during surgery. Histopathological analysis was
performed according to the scoring system published by Kleiner and
al. [56]. Four histopathological features were semi-quantitatively
evaluated: grade of steatosis (0, ,5%; 1, 5%–30%; 2, .30%–60%; 3,
.60%), lobular inflammation (0, no inflammatory foci; 1, ,2
inflammatory foci per 200x field; 2, 2–4 inflammatory foci per 200x
field; 3, .4 inflammatory foci per 200x field), hepatocellular
ballooning (0, none; 1, few balloon cells; 2, many cells/prominent
ballooning), and fibrosis stage (from 0, none to 4, cirrhosis). Visceral
adipose tissue samples were also obtained from 18 patients and frozen
until analyzed. All subjects gave their informed written consent to
participate in this research study according to French legislation
regarding Ethic and Human Research (Huriet-Serusclat law). The
‘‘Comite ´ Consultatif de Protection des Personnes dans la Recherche
Biome ´dicale de Nice’’ approved this study (07/04:2003, Nu 03.017).
Control subjects: Total RNA from 6 control livers was purchased from
Stratagene (La Jolla, CA), Clontech (Mountain View, CA) and
Biochain (Hayward, CA). The Stratagene and Biochain companies
confirmed that histological findings were completely normal with no
evidence of fatty liver disease. No clinical or biological data were
available for these individuals but the absence of inflammatory process
was corroborated by low CRP mRNA expression levels, as previously
reported [10,11]. Control subcutaneous adipose tissue was obtained
from 4 lean subjects (2 females and 2 males; age, 37611 years; BMI,
22.160.7 kg/m
2) undergoing lipectomy for cosmetic purpose.
Sera from 9 lean patients and 70 morbidly obese patients (15 S0
patients, 23 S3 patients and 23 NASH patients with severe
steatosis) were used to evaluate the circulating levels of IL6, TNFa,
IP10 and MCP1 (realized by the IFR150, Toulouse, France) using
the Milliplex Map from Millipore and endotoxin levels (LAL
QCL-1000, Lonza). The abundances of palmitate as expressed
relative to their values in a commercial serum sample (Sigma
Aldrich, Ref. H4522) were evaluated in 25 morbidly obese patients
using liquid chromatography-mass spectrometry (LC/MS).
Real-time quantitative PCR analysis
Total RNA was extracted from human tissues using the RNable
total RNA extraction kit (Eurobio, France) for liver biopsy and
RNeasy Mini Kit (Qiagen, Contraboeuf, France) for adipose
tissue. The samples were treated by Turbo DNA-free (Applied
Biosystems, Contraboeuf, France) following the manufacturer’s
protocols. The quantity and quality of the isolated RNA were
determined using the Agilent 2100 Bioanalyser with RNA 6000
Nano Kit (Agilent Technologies). Total RNA (1 mg) was reverse-
transcribed with High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA). Real-time quantitative
PCR was performed using the ABI PRISM 7900/7500 Fast Real
Time PCR System and FAM dyes (Applied Biosystems, Contra-
boeuf, France) following the manufacturer’s protocols in our
Genomics facilities. The TaqMan gene expression assays were
purchased from Applied Biosystems (Table S1). Gene expression
values were normalized to the value of the housekeeping gene
RPLP0 (Ribosomal Phosphoprotein Large P0) and calculated
based on the comparative cycle threshold Ct method (2
-DDCt).
Statistical analysis
Statistical significance of differential gene expression between
two study groups was determined using the non-parametric
Kruskal-Wallis test with the DCt of each group. P,0.05 was
considered as significant. However, the genes with either less than
1.5 fold of difference between two groups or a difference due to
one patient in one group were no further considered as
significantly modified.
Supporting Information
Table S1 Genes included in this study
Found at: doi:10.1371/journal.pone.0013577.s001 (0.10 MB
PDF)
Table S2 Differentially expressed genes in visceral adipose tissue
of NASH patients versus S0 and S3 patients
Found at: doi:10.1371/journal.pone.0013577.s002 (0.08 MB
PDF)
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